Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for prevention of stroke

Journal of General Internal Medicine

Volumn 14, Issue 12, 1999, Pages 763-774

  Warshafsky, Stephen ^a   Packard, David ^a   Marks, Stephen J ^a   Sachdeva, Neeraj ^a   Terashita, Dawn M ^a   Kaufman, Gabriel ^a   Sang, Koky ^a   Deluca, Albert J ^a   Peterson, Stephen J ^a   Frishman, William H ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Cholesterol; HMG CoA reductase inhibitors; Meta analysis; Stroke prevention

Indexed keywords

CHOLESTEROL; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ARTICLE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFICACY; EVIDENCE BASED MEDICINE; FATALITY; HIGH RISK PATIENT; HUMAN; META ANALYSIS; OUTCOMES RESEARCH; SECONDARY PREVENTION; STROKE;

AGED; CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVALS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; ODDS RATIO; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; REGRESSION ANALYSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0033428859     PISSN: 08848734     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1497.1999.02109.x     Document Type: Article

References (116)

1. st century. Arch Intern Med. 1997;157:1177-84.
2. 2. Iso H, Jacobs DR. Wentworlh D, Neaton JD, Cohen JD. Serum cholesterol levels and six year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial (MRFIT). N Engl J Med. 1989;320:904-10.
3. 3. Yano K, Reed DM, MacLean CJ. Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program. Stroke. 1989;20: 1460-5.
4. 4. Ooneda G, Yoshida Y, Suzuki K, et al. Smooth muscle cells in the development of plasmatic arterionecrosis, arteriosclerosis, and arterial contraction. Bloodvessels. 1978;15:148-56.
5. 5. Yamori Y. Horie R, Ohtaka M, Nara Y, Fukase M. Effect of hypercholestcrolemic diet on the incidence of cerebrovascular and myocardial lesions in spontaneously hypertensive rats (SHR). Clin Exp Pharmacol Physiol. 1976;3(suppl 3):205-8.
6. 6. Atkins D, Psaty BM, Koepsell TD. Longstreth WT Jr, Larson EB. Cholesterol reduction and the risk for stroke in men: a meta-analysis of randomixed, controlled trials. Ann Intern Med. 1993;119: 136-45.
7. 7. Hebert PR, Gaztano JM, Hennekens CH. An overview of trials of cholesterol lowering and risk of stroke. Arch Intern Med. 1995;155:50-5.
8. 8. Furberg CD, Adams HP Jr, Applegate WB, et al, for the Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation. 1994;90:1679-87.
9. 9. Salonen R, Nyyssonen K, Porkkala E, et al. Kuopio Atherosclerosis Prevention Study (KAPS): a population-based primary preventative trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation. 1995;92:1758-64.
10. 10. Crouse JR III, Byington RP, Bond MG, et al. Pravastatin. Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol. 1995;75:455-9.
11. 11. Mercuri M, Bond MG, Sirtori CR, et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study (CAIUS). Am J Med. 1996;101: 627-34.
12. 12. Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation. 1995;92:2419-25.
13. 13. Breslow NE, Day NE. The Analysis of Case-Control Studies. Statistical Methods in Cancer Research; vol 1. Lyon, France: IARC Scientific Publications; 1980:139.
14. 14. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemlol Rev. 1987;9:1-30.
15. 15. Shepherd J, Cobbe SM, Ford I, et al. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-7.
16. 16. Weintraub WS, Boccuzzi SJ, Klein JL, et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl J Med. 1994;331:1331-7.
17. 17. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med. 1993;119: 969-76.
18. 18. Pitt B, Mancini GB, Ellis SG, Rosman HS, Park JS, McGovern ME. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol. 1995;26:1133-9.
19. 19. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovaslatin (EXCEL) study results, I: efficacy in modifying plasma lipoproteins and adverse event profile in 8,245 patients with moderate hypercholesterolemia. Arch Intern Med. 1991;151:43-9.
20. 20. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypcreholesterolemia with combined drug regimens. JAMA. 1990;264:3007-12.
21. 21. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicenter Anti-Atheroma Study (MAAS). Lancet. 1994;344: 633-8.
22. 22. Palerson RW, Paal JJ, Steele CH. Hathaway SC. Wong JG. Impact of intensive lipid modulation on angiographically defined coronary disease: clinical implications. South Med J. 1994;87:236-42.
23. 23. Plosker GL, McTavish D. Simvastatin: a reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolemia. Drugs. 1995;50:334-63.
24. 24. Jones PH. Lovastatin and simvastatin prevention studies. Am J Cardiol. 1990;66:39B-43B.
25. 25. Simes RJ. Prospective meta-analysis of cholesterol-lowering studies: the Prospective Pravastatin Pooling (PPP) project and the Cholesterol Treatment Trialists (CTT) collaboration. Am J Cardiol. 1995;76:122C-126C.
26. 26. Todd PA, Goa KL. Simvastalin: a review of its pharmacological properties and therapeutic potential in hypercholesterolemia. Drugs. 1990;40:583-607.
27. 27. Crouse JR, Byington RP. Bond MG, et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries: design features of a clinical trial with carotid atherosclerosis outcome. Control Clin Trials. 1992;13:495-506.
28. 28. Bradford RH, Shear CL. Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study: design and patient characteristics of a double-blind, placebo-controlled study in patients with moderale hypercholesterolemia. Am J Cardiol. 1990; 66:44B-55B.
29. 29. Tonkin AM. Management of the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study after the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol. 1995: 76:107C-112C.
30. 30. Foley DP, Bonnier H, Jackson G, et al. Prevention of reslenosis after coronary balloon angioplasty: rationale and design of the Fluvastatin Angioplasty Restenosis (FLARE) Trial. Am J Cardiol. 1994;73:50D-61D.
31. 31. Slewart BF, Brown BG, Zhao XQ. et al. Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein and cholesterol. J Am Coll Cardiol. 1994;23:899-906.
32. 32. Zhao XQ. Brown BG, Hillger L, et al. Effects of Intensive lipid-lowering therapy on the coronary arteries of asymptomatic subjects with elevated apolipoprotein B. Circulation. 1999;88:2744-53.
33. 33. Pfeffer MA, Sacks FM, Moye LA, et al. Cholesterol and Recurrent Events: a secondary prevention trial lor normolipidemic patients. Am J Cardiol. 1995;76:98C-106C.
34. 34. Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein (a). JAMA. 1995;274:1771-4.
35. 35. Guptha S. Profiling a landmark clinical trial: Scandinavian Simvastatin Survival Study. Curr Opin Lipidol. 1995;6:251-3.
36. 36. The West of Scotland Coronary Prevention Study Group. Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. Am J Cardiol. 1995;76:485-91.
37. 37. Design features and baseline characteristics of the LIPID study: a randomized trial in patients with previous acute myocardial infaretion and/or unstable angina pectoris. Am J Cardiol. 1995; 76:474-9.
38. 38. Stoy DB, Curtis RC, Dameworth KS, et al. The successful recruitment of elderly black subjects in a clinical trial: the CRISP [Cholesterol Reduction in Seniors Program] experience. J Natl Med Assoc. 1995;87:280-7.
39. 39. Waters D, Higginson L, Gladstone P, Kimball B, LeMay M, Lesperance J. Design features of a controlled clinical trial to assess the effect of an HMG-CoA reductase inhibitor on the progression of coronary artery disease. Control Clin Trials. 1993;14:45-74.
40. 40. Stehbens WE. Validity of the 4S simvastalin trial. Lancet. 1995; 345:264. Letter.
41. 41. Design, rationale, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project-a combined analysis of three large-scale randomized trials: Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). Am J Cardiol. 1995;76:899-905.
42. 42. Sacks FM, Pfeffer MA, Moye L, et al. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE). Am J Cardiol. 1991;68:1436-46.
43. 43. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9.
44. 44. Jukema JW, Bruschke AV, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Stalin Study (REGRESS). Circulation. 1995;91:2528-40.
45. 45. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200-300 mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol. 1993;72: 1031-7.
46. 46. Sacks FM, Pfeffer MA, Moye LA. et al, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-9.
47. 47. Brown G, Albers JJ, Fisher LD. et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-98.
48. 48. Sacks FM, Pasternak RC, Gibson CM. Rosner B, Stone PH, for the Harvard Atherosclerosis Reversibility Project (HARP) Group. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Lancet. 1994;344:1182-6.
49. 49. Brensike JF, Levy RI, Kelsey SF, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation. 1984;69:313-24.
50. 50. Buchwald H, Varco RL, Malts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. N Engl J Med. 1990; 323:946-55.
51. 51. Watts GF, Lewis B, Brunt JN, et al. Effects on coronary artery disease of lipid-lowering diet or diet plus cholestyramine in St. Thomas' Atherosclerosis Regression Study (STARS). Lancet. 1992; 339:563-9.
52. 52. Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial (CCAIT). Circulation. 1994;89:959-68.
53. 53. The Multicenter European Research Trial with Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Circulation. 1992; 86:100-10.
54. 54. Waters D, Craven TE, Lesperance J. Prognostic significance of progression of coronary atherosclerosis. Circulation. 1993;87: 1067-75.
55. 55. Craven TE, Ryu JE, Espeland MA, et al. Evaluation of the associations between carotid artery atherosclerosis and coronary artery stenosis: a case-control study. Circulation. 1990;82:1230-42.
56. 56. Salonen R, Salonen JT. Progression of carotid atherosclerosis and its determinants: a population-based ultrasonography study. Athcrosclerosis. 1990;81:33-40.
57. 57. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safely of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-45.
58. 58. Sahni R, Maniet AR, Vori G, Banka VS. Prevention of restenosis by lovastatin after successful coronary angioplasty. Am Heart J. 1991;121:1600-8.
59. 59. Haskell WL, Alderman EL, Fair JM, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease: the Stanford Coronary Risk Intervention Project (SCRIP). Circulation. 1994;89:975-90.
60. 60. Furberg CD, Pitt B, Byington RP, Park JS, McGovern ME, for the PLACI and PLACII Investigators. Reduction in coronary events during treatment with pravaslalln. Am J Cardiol. 1995;76: 60C-63C.
61. 61. Holme I. Cholesterol reduction and its impact on coronary artery disease and total mortality. Am J Cardiol. 1995;76:10C-17C.
62. 62. Gould AL, Rossouw JE, Santanello NC. Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: a new look at old data. Circulation. 1995:91:2274-82.
63. 63. Cummings P, Psaty BM. The association between cholesterol and death from injury. Ann Intern Med. 1994;120:848-55.
64. 64. Kuo PT. Dyslipidemia and coronary artery disease. Clin Cardiol. 1994;17:519-27.
65. 65. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ. 1990;301:309-14.
66. 66. Brown BG, Zhao XQ. Sacco DE, Albers JJ. Lipid lowering and plaque regression: new Insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 1993; 87:1781-91.
67. 67. Holme I. Relation of coronary heart disease incidence and total mortality to plasma cholesterol reduction in randomized trials: use of meta-analysis. Br Heart J. 1993;69(suppl 1):42-7.
68. 68. Jacobs D, Blackburn H, Higgins M. et al. Report of the conference on low blood cholesterol: mortality associations. Circulation. 1992;86:1046-60.
69. 69. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischacmic heart disease? BMJ. 1994;308:367-72.
70. 70. Law MR. Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. BMJ. 1994;308:373-9.
71. 71. Superko MR. Krauss RM. Coronary artery disease regression: convincing evidence for the benefit of aggressive lipoprotein management. Circulation. 1994;90:1056-69.
72. 72. Marchioli R, Marfisi RM, Carinci F, Tognoni G. Meta-analysis, clinical trials, and transferability of research results into practice: the case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease. Arch Intern Med. 1996;156: 1158-72.
73. 73. Holme I. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation. 1990;82:1916-24.
74. 74. Shepherd J. Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety. Eur Heart J. 1995;16:5-13.
75. 75. Furberg CD, Crouse JR, Byington RP, Bond MG, Espeland MA. PLAC-II: effects of pravastatin on progression of carotid atherosclerosis and clinical events. J Am Coll Cardiol. I993;21(suppl 2):71. Abstract.
76. 76. Maher VM, Brown BG, Marcovina SM, et al. The adverse effect of lipoprotein (a) on coronary atherosclerosis and clinical events is eliminated by substantially lowering LDL cholesterol. J Am Coll Cardiol. 1994:23(suppl 1): 131. Abstract.
77. 77. Pitt B, Mancini J. Ellis SG, Rosman HS, McGovern ME. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC-I). J Am Coll Cardiol. 1994;23(suppl 1):131. Abstract.
78. 78. Thompson GR. The familial hypercholesterolemia regression study (FHRE). J Am Coll Cardiol. 1994;23(suppl 1):131. Abstract.
79. 79. Lacoste LL, Lam JY, Hung J. Waters D. Pravachol decreases platelet thrombus formation in hypercholesterolemic coronary patients in conjunction with improvements in serum lipids. J Am Coll Cardiol. 1994;23(suppl 1):131. Abstract.
80. 80. van Boven AJ, Jukema JW, Bal ET, Reiber JH, Bruschke AV. Remodeling of coronary artery lesions: regression to the mean or effect of cholesterol-lowering therapy? J Am Coll Cardiol. 1994; 23(suppl 1): 132. Abstract.
81. 81. Lund GK, Pfalzer B, Beisiegel U, Beil U, Greten H, Hamm CW. Treatment of severe hypercholesterolemia and coronary heart disease by simvastatin and LDL apheresis (HELP): effects on coronary lesions. J Am Coll Cardiol. 1994:23(suppl 1):132. Abstract.
82. 82. The Scandinavian Simvastatin Survival Study Group. Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction. Am J Cardiol. 1993;71:393-400.
83. 83. Bradford RH, Downton M, Chremos AN. et al. Efficacy and tolerability of lovaslatin in 3390 women with moderate hypercholesterolemia. Ann Intern Med. 1993;118:850-5.
84. 84. Frick MH, Heinonen OP, Huttunen JK, Koskinen P. Manttari M. Manninen V. Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease: an ancillary study in the Helsinki Heart Study frame population. Ann Med. 1993;25:41-5.
85. 85. Furberg CD, Byinglon RP, Crouse JR, Espeland MA. Pravastatin, lipids, and major coronary events. Am J Cardiol. 1994;73:1133-4.
86. 86. Hodis HN, Mack WJ, Azen SP, et al. Triglyceride-and cholesterol-rich lipoprotcins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation. 1994; 90:42-9.
87. 87. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two year efficacy and safety follow-up. Am J Cardiol. 1994;74:667-73.
88. 88. Shepherd J. The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men. Am J Cardiol. 1995;76:113C-117C.
89. 89. Heady JA, Morris JN, Oliver MF. WHO clofibrate/cholesterol trial: clarifications. Lancet. 1992;340:1405-6.
90. 90. Pitt B, Ellis SG, Mancini GBJ, Rosman US, McGovern ME. Design and recruitment in the United States of a multicenter quantitative angiographie trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I). Am J Cardiol. 1993;72:31-5.
91. 91. Espeland MA, Hoen H. Byington R, Howard G, Riley WA, Furberg CD. Spatial distribution of carotid intimal-medial thickness as measured by B-mode ultrasonography. Stroke. 1994;25:1812-9.
92. 92. The West of Scotland Coronary Prevention Study Group. A coronary primary prevention study of Scottish men aged 45-64 years: trial design (WOSCOPS). J Clin Epidemiol. 1992;45:849-60.
93. 93. Davey Smith G, Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? BMJ. 1992;304:431-4.
94. 94. Simes RJ, Glasziou PP. Meta-analysis and quality of evidence in the economic evaluation of drug trials. Pharmacoeconomics 1992;1: 282-92.
95. 95. Chalmers TC. Problems induced by meta-analyses. Stat Med. 1991;10:971-80.
96. 96. Dickersin K, Berlin JA. Meta-analysis: state-of-the-science. Epidemiol Rev. 1992;14:154-76.
97. 97. Simes RJ. Publication bias: the case for an international registry of clinical trials. J Clin Oncol. 1986;4:1529-41.
98. 98. Gordon DJ. Cholesterol Lowering and Total Mortality: Contemporary Issues in Cholesterol Lowering: Clinical and Population Aspects. New York, NY: Marcel Dekker Inc; 1994.
99. 99. Oliver MF. Might treatment of hypercholesterolemia increase non-cardiac mortality? Lancet. 1991;337:1529-31.
100. 100. The Asymptomatic Carotid Artery Plaque Study Group. Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). Control Clin Trials. 1992;13:293-314.
101. 101. Crouse SR, Byinglon PR, Furberg CD. Reductase inhibitor monotherapy prevents stroke. Circulation. 1996;94(suppl 1):540. Abstract.
102. 102. Sacco RL, Wolf PA, Kannel WB, McNamara PM. Survival and recurrence following stroke: the Framingham Study. Stroke. 1982; 13:290-5.
103. 103. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. A prospective study of aeute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project-1981-86, 2: incidence, case fatality rates and overall outcome at one year of cerebral infarction, primary intracerebral and subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry. 1990;53:16-22.
104. 104. Bamford J, Sandercock, P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet. 1991;337:1521-6.
105. 105. Konishi M, Iso H, Komachi Y, et al. Associations of serum total cholesterol, different types of stroke, and stenosis distribution of cerebral arteries: the Akita Pathology Study. Stroke. 1993;24:954-64.
106. 106. Brown RD, Whisnant JP, Sicks JD, O'Fallon WM. Wiebers DO. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke. 1996;27:373-80.
107. 107. Wolf PA, D'Agostino RB, O'Neal MA, et al. Secular trends in stroke incidence and mortality: the Framingham Study. Stroke. 1992;23: 1551-5.
108. 108. Robins M. Baum HM. The National Survey of Stroke Incidence. Stroke. 1981;12 (2 pt 2 suppl 1):145-157.
109. 109. Howard G, Anderson R, Sorlie P, Andrews V, Backlund E, Burke GL. Ethnic dilTerenees in stroke mortality between non-Hispanic whites, Hispanic whites, and Hacks: the National Longitudinal Mortality Study. Stroke. 1994;25:2120-5.
110. 110. Gillum RF. Stroke in blacks. Stroke. 1988;19:1-9.
111. 111. Rosenson RS, Tangney CC. Antiatherothrombotic properties of slalins: implications for cardiovascular event reduction. JAMA. 1998;279:1643-50.
112. 112. Crouse JR III, Byington RP, Hoen HM, Furberg CD. Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med. 1997;157:1305-10.
113. 113. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA. 1997;278:313-21.
114. 114. Blauw GJ, Lagaay AM, Smelt AH, Westendorp RG. Stroke, statins, and cholesterol: a meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke. 1997;28:946-50.
115. 115. Bucher HC, Griffith LE, Guyatt GH Effect of HMG-coA reductase inhibitors on stroke: a meta-analysis of randomized, controlled trials. Ann Intern Med. 1998;128:89-95.
116. 116. Fleiss JL. Statistical Methods for Rales and Proportions. 2nd ed. New York, NY: John Wiley and Sons; 1981:33-49.